Table 3.
Inverse-probability-weighted regression-adjustment analyses of patient-reported data from the EuroQol Five-Dimensions tool, Work Productivity and Activity Impairment Questionnaire, and the Hamburg Quality of Life Questionnaire in Multiple Sclerosis comparing ABCRE therapies and DMF therapy
| Outcome | Base (n) | ABCRE therapy | DMF average treatment effect | p value |
|---|---|---|---|---|
| WPAI: percentage work time missed (absenteeism) | 154 | 2.06 (0.46–3.67) | −2.06 (−3.67 to −0.46) | 0.012 |
| WPAI: percentage work time impaired (presenteeism) | 158 | 19.45 (16.26–22.64) | −12.97 (−18.87 to −7.08) | <0.001 |
| WPAI: percentage overall work impairment | 152 | 20.92 (17.38–24.46) | −13.92 (−19.86 to −7.98) | <0.001 |
| WPAI: percentage activity impairment | 243 | 25.31 (21.99–28.63) | −17.26 (−23.50 to −11.03) | <0.001 |
| EQ-5D | 255 | 0.823 (0.793–0.852) | 0.075 (0.014 to 0.136) | 0.016 |
| EQ-VAS | 252 | 74.55 (72.54–76.55) | 10.84 (6.15 to 15.53) | <0.001 |
| HAQUAMS fatigue/thinking subscale | 245 | 1.90 (1.77–2.03) | −0.47 (−0.75 to −0.19) | 0.001 |
| HAQUAMS mobility/lower limb subscale | 233 | 1.84 (1.72–1.95) | −0.43 (−0.75 to −0.11) | 0.009 |
| HAQUAMS mobility/upper limb subscale | 247 | 1.38 (1.30–1.46) | −0.15 (−0.32 to 0.02) | 0.075 |
| HAQUAMS social function subscale | 248 | 2.05 (1.96–2.15) | −0.54 (−0.77 to −0.31) | <0.001 |
| HAQUAMS mood subscale | 250 | 2.40 (2.28–2.53) | −0.45 (−0.64 to −0.26) | <0.001 |
| HAQUAMS total | 227 | 1.95 (1.86–2.04) | −0.45 (−0.61 to −0.29) | <0.001 |
EQ-5D, EuroQol Five-Dimensions tool; WPAI, Work Productivity and Activity Impairment Questionnaire; HAQUAMS, Hamburg Quality of Life Questionnaire in Multiple Sclerosis comparing ABCRE therapies and DMF therapy